Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s “4+1” Biomedical and High-end Medical Device Industry Fund and Qihang Investment Management Co., Ltd., with Lighthouse Capital serving as the exclusive financial advisor. The funds will propel the Phase III clinical trial of CXG87, a modified budesonide/formoterol inhalation powder aerosol, and drive the development of multiple innovative inhalation powder aerosols.
Company Focus and Product Pipeline
Dedicated to the research and development of innovative inhalation powder aerosols, Chance Pharmaceuticals leverages two major development platforms: grinding mixing and spray drying. The company’s core product, CXG87, is in Phase III clinical trials and is expected to submit a marketing application in the first half of 2026.
Innovative Drug Development and Collaborations
The company’s pipeline features several innovative nanobody and small-molecule inhalation powder aerosols on track to enter clinical stages in 2026. Chance Pharmaceuticals has also collaborated with well-known domestic and international pharmaceutical companies, including Yiling Pharmaceuticals, on the development of innovative inhalation drug molecules. Looking ahead, the company remains committed to advancing inhalation drug innovation to provide safer and more efficient treatment options for patients worldwide.-Fineline Info & Tech
Leave a Reply